Thromboembolic prophylaxis with danaparoïd (Orgaran) in a high-thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia (HIT) and Widal's disease

Clin Appl Thromb Hemost. 2000 Oct;6(4):187-9. doi: 10.1177/107602960000600401.

Abstract

There is no consensus concerning thromboembolic prophylaxis in high-risk pregnant women with a previous history of heparin-induced thrombocytopenia. An alternative anticoagulant therapy is danaparoïd, whereas unfractioned and low-molecular-weight heparin therapy is contraindicated. We report a case of successful thrombosis prophylaxis using danaparoïd in a high-thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia during a previous pregnancy and Widal's disease.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anticoagulants / administration & dosage
  • Aspirin / adverse effects
  • Asthma / chemically induced
  • Asthma / complications
  • Cephalosporins / adverse effects
  • Chondroitin Sulfates / administration & dosage*
  • Dermatan Sulfate / administration & dosage*
  • Drug Combinations
  • Drug Hypersensitivity
  • Female
  • Heparin / adverse effects
  • Heparinoids / administration & dosage
  • Heparitin Sulfate / administration & dosage*
  • Humans
  • Pregnancy
  • Pregnancy Complications, Hematologic / blood
  • Pregnancy Complications, Hematologic / drug therapy*
  • Risk Factors
  • Thrombocytopenia / blood
  • Thrombocytopenia / chemically induced
  • Thrombocytopenia / complications
  • Thromboembolism / drug therapy
  • Thromboembolism / prevention & control*

Substances

  • Anticoagulants
  • Cephalosporins
  • Drug Combinations
  • Heparinoids
  • Dermatan Sulfate
  • Heparin
  • Chondroitin Sulfates
  • Heparitin Sulfate
  • danaparoid
  • Aspirin